Neem Holdings

Neem Biotech is a drug discovery company based in Abertillery, Wales, that specializes in developing novel antimicrobial and anti-virulence therapies to combat antibiotic resistance. Founded in 1998, the company identifies and synthesizes bioactive compounds from natural sources, such as garlic and the neem tree, to disrupt bacterial quorum sensing and biofilm formation. This unique approach aims to sensitize bacteria to existing treatments and manage chronic infections in conditions like cystic fibrosis and non-healing wounds. Currently operating as a subsidiary of the InQpharm Group, Neem Biotech follows a strategy of de-risking early-stage assets before spinning them out into specialized companies, such as Onya Therapeutics for wound care and Mariposa Therapeutics for rare skin diseases. The company's lead research includes synthetic ajoene analogues designed to interfere with bacterial-host interactions without promoting further resistance.